News Kite expands manufacturing capacity for CAR-T therapies Less than a year after it was acquired by Gilead in a $11.9 billion deal,
News Natural killer cells 'a hundred times cheaper' than CAR-T Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost.
Partner Content Partner Content CAR:T - Has biology outpaced the ability to deliver? Experts comment on manufacturing of CAR-T
Events Partner Content CAR-T Congress USA | 20 - 22 March 2018 | Boston Targeting | Commercialization | Scalability
Events Partner Content Combined CAR-T Congress Europe | 30 - 31 Jan 2018 Hear more about how to maximize CAR-T cell therapy
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
